-

Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (TSE:4528), today announced that Toichi Takino, President and COO, presented at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.

An audio recording of the event is available here and accessible until February 15, 2026.

About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.

Contacts

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono-pharma.com

Industry:

Ono Pharmaceutical Co., Ltd.

TOKYO:4528
Release Versions
English

Contacts

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono-pharma.com

More News From Ono Pharmaceutical Co., Ltd.

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology

OSAKA, Japan & MONTREAL--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that it has entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; “Congruence”) for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology. In December 2024, we entere...

Ono to Participate in the 44th Annual J.P. Morgan Healthcare Conference

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (TSE:4528) today announced that Toichi Takino, President and COO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. A live webcast of the event will be available here and accessible for 30 days following the presentation. About Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its ph...

Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") announced that efficacy signals for ONO-2808, a S1P5 receptor agonist, were observed in the interim analysis of the Phase 2 clinical trial (ONO-2808-03 study) which assessed the safety and efficacy of ONO-2808 compared to placebo in patients with multiple system atrophy (MSA). In the exploratory interim analysis of this study, it was observed that the progression of...
Back to Newsroom